Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer:

Jiaqi Han,Desheng Xiao,Chongqing Tan,Xiaohui Zeng,Huabin Hu,Shan Zeng,Qin Jiang,Longjiang She,Linli Yao,Li Li,Lanhua Tang,Jian Ma,Jin Huang,Liangfang Shen

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer:

2020

Jiaqi Han
Desheng Xiao
Chongqing Tan
Xiaohui Zeng
Huabin Hu
Shan Zeng
Qin Jiang
Longjiang She
Linli Yao
Li Li
Lanhua Tang
Jian Ma
Jin Huang
Liangfang Shen

Background:The FIRE-3 phase III clinical trial demonstrated the marked advantage of prolonging the median overall survival of patients with final RAS wild-type (WT) left-sided metastatic colorectal...

Keywords:

Clinical trial
General surgery
FOLFIRI
Colorectal cancer
Wild type
Oncology
Cost-effectiveness analysis
Bevacizumab
Cetuximab
Medicine
Internal medicine
first line
cost effectiveness
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations